Coverage
-
July 22, 2021
Drugmaker Acer Therapeutics Inc. has agreed to pay $8.35 million to end investor claims that it misrepresented conversations it had with the U.S. Food and Drug Administration, which allegedly hurt investors when its share prices fell after the FDA rejected a new drug application the company had submitted.
3 other articles on this case.
View all »